Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tomoyuki Nagata has a total of 55 co-authors. Here are the top co-authors by number of shared publications:

  • Shunichiro Shinagawa

    The Jikei University School of Medicine, The Jikei University School of Medicine

    20 shared publications
  • Kazuhiko Nakayama

    Department of Psychiatry, The Jikei University School of Medicine, Tokyo, Japan

    18 shared publications
  • Shunichiro Shinagawa

    Department of Psychiatry The Jikei University School of Medicine Tokyo Japan

    13 shared publications
  • Hisashi Yamada

    Division of Molecular Genetics, Institute of DNA Medicine, The Jikei University School of Medicine, Tokyo, Japan

    8 shared publications
  • Masahiro Shigeta

    Department of Psychiatry The Jikei University School of Medicine Tokyo Japan

    7 shared publications
  • Shinichiro Nakajima

    Department of Neuropsychiatry, Keio University School of Medicine, Keio University School of Medicine, Tokyo, Japan

    7 shared publications

Latest Publications

  • Open Access

    The trajectory of delusions in patients with Alzheimer's disease receiving pharmacological treatment: A re-analysis of data from the CATIE-AD trial

    by Katsuharu Yano, Tomoyuki Nagata, Shinichiro Nakajima, Shinsuke Kito, Shunichiro Shinagawa

    Background: Previous studies have reported decreases in the proportion of patients with delusions and severity of delusions during long-term follow-up in Alzheimer's disease (AD). Objective: The aim of the present study was to explore clinical predictors of the disappearance of delusions in AD patients enrolled in the Clinical Antipsychotic Trials of Intervention Effectiveness–Alzheimer's Disease (CATIE-AD) trial who received pharmacological treatment. Methods: We re-analyzed the data of 421 clinic-based patients enrolled in the CATIE-AD trial to examine the association between the disappearance of delusions and relevant factors selected by reference to previous studies at week 12, 24, and 36 of treatment. Generalized Estimating Equations were used to analyze the impact of the assigned medication (mainly atypical antipsychotics), treatment duration, and their interaction on the disappearance of delusions over time. Results: The proportion of patients with delusions (PWD) gradually decreased to approximately 50% over the 36-week treatment period; however, no significant differences in the baseline variables were identified between the PWD and patients without delusions (POD) at any of the follow-up time-points (weeks 12, 24, or 36). Furthermore, the treatment duration was found to contribute significantly to the disappearance of delusions over time (conversion from PWD at baseline to POD at subsequent follow-up visits), independent of active drug use. Conclusions: Disappearance of delusions in AD patients was associated with the interval from the baseline, regardless of the use of active drugs. Insights into the natural course of delusions could guide clinicians toward selecting alternative treatment strategies for patients with AD.

  • Patient‐Specific Clinical Formulation for Agitation in Alzheimer's Disease: Beyond Group‐Level Evidence

    by Shunichiro Shinagawa, Tomoyuki Nagata

    Agitation in Alzheimer's disease (AD) is clinically heterogeneous. Patients who meet the same syndromic definition can differ in the behaviour of greatest concern, the factors that precipitate or sustain it, the risks involved and their response to treatment. Randomised trials are essential for estimating average treatment effects; individual treatment selection also requires patient‐specific clinical information. This review considers patient‐specific clinical formulation as a practical way to connect group‐level evidence with individual treatment decisions. The formulation makes explicit what is being treated, which contributors are plausible, which contextual or reversible factors matter, what outcome would count as meaningful improvement and when treatment should be changed or stopped. Treatment response then becomes additional clinical information: early benefit, adverse effects or an unexpected course may support or call into question the initial formulation. Non‐pharmacological care and treatment of reversible causes remain the foundation of management, with medication reserved for agitation that is severe, persistent, dangerous or highly distressing. For Japan, we propose a formulation summary as a prototype for shared documentation across care settings; its feasibility and clinical value require prospective evaluation. Moving beyond group averages entails applying evidence more carefully to the needs of the individual patient.

  • Toward Precision Neuropsychiatry of Dementia: Neuropsychiatric Symptoms as Multidimensional Clinical Phenotypes

    by Shunichiro Shinagawa, Tomoyuki Nagata

    Neuropsychiatric symptoms (NPS) are the most clinically consequential manifestations of dementia, yet they are frequently underestimated as secondary behavioural complications. This review introduces a precision neuropsychiatry framework that conceptualises NPS—including apathy, agitation, psychosis, depression, and sleep disturbances—as multidimensional clinical phenotypes. These phenotypes bridge neurodegeneration, biological aging, brain network disruption, psychosocial context, functional decline, and caregiver burden. We trace the conceptual evolution from dementia to neurocognitive disorders, and from behavioural and psychological symptoms of dementia (BPSD) to NPS and mild behavioural impairment (MBI). Precision neuropsychiatry stratifies NPS based on disease background, clinical stage, neural networks, biological aging, physical vulnerability, and psychosocial context to optimise differential diagnosis, prognostic prediction, and targeted interventions. Although conventional symptom‐based classification remains practically useful, it must be complemented by biological, functional, and contextual stratification; identical symptom labels often arise from distinct mechanisms and express differently based on personality, life history, environmental mismatch, and available resources. Emerging evidence from MBI, neuroimaging, brain‐age paradigms, frailty, neuroinflammation, Alzheimer's disease (AD) biomarkers, and international consensus criteria supports this multidimensional shift. Future research should advance from cross‐sectional symptom descriptions toward longitudinal, mechanism‐informed, and context‐sensitive models to translate these findings into real‐world psychogeriatric care.

  • Open Access

    Family Caregiver Burden and Neuropsychiatric Symptoms in Japanese Community‐Dwelling People With Alzheimer's Disease: A Cross‐Sectional Study Using a Web‐Based Questionnaire

    by Tomoyuki Nagata, Shunichiro Shinagawa, Shinichi Noto, Kentaro Yamato, Naoki Mori, Keisuke Onuki

    Background: Previous studies of community‐dwelling people with Alzheimer's disease (AD) have reported an association between the severe neuropsychiatric symptoms (NPS) of dementia and caregiver burden. We explored the current status of family caregiver burden, NPS of dementia, and care service usage in Japanese community‐dwelling people with AD. Methods: A web‐based questionnaire was administered to cohabitant family caregivers of community‐dwelling people with AD from 13 to 27 November 2023. Amongst 8108 participants registered in the panel data, 705 family caregivers (age: 19–79 years) were selected. Participants completed the Japanese version of the Neuropsychiatric Inventory‐Brief Questionnaire. Results: Family caregivers ( n = 705) had a mean ± standard deviation (SD) age of 54.6 ± 11.5 years, 56.9% were male, and 84.0% cared for a parent or in‐law with AD. Patients with AD had a mean ± SD age of 84.2 ± 8.8 years; 26.2% were male, and 90.6% had NPS, including 73.4% with hyperactivity (agitation, disinhibition, irritability and aberrant motor behaviour). Mean ± SD caregiving time per week was higher for caregivers of patients with NPS versus without NPS (24.1 ± 22.1 vs. 17.6 ± 14.0 h). The dissatisfaction with nursing care support services was higher amongst caregivers of patients with NPS vs. without NPS. To manage hyperactivity, 11.3% of caregivers administered medication and 11.5% relocated patients to a calm environment; 16.6% of the caregivers had no way to cope. Amongst caregivers who responded ‘administer medication’ in response to hyperactivity, 32.1% had care staff or a medical provider come in and administer oral medication and 18.9% took the patient to a medical facility to receive an injection or intravenous treatment. Conclusions: Caregiving for AD patients with NPS (vs. without NPS) was associated with longer duration of caregiving, greater usage of nursing care services and dissatisfaction with nursing care support services.


  • Top Cited Papers
    Open Access

    Caregiver burden and quality of life associated with behavioral and psychological symptoms of Alzheimer's disease: A web-based cross-sectional survey study

    by Shunichiro Shinagawa, Tomoyuki Nagata, Shinichi Noto, Kentaro Yamato, Naoki Mori, Keisuke Onuki

    Background: Behavioral and psychological symptoms of dementia (BPSD) in patients with Alzheimer's disease (AD) may seriously impact caregiver burden and, therefore, quality of care. Objective: To clarify the association of BPSD and BPSD subtypes with caregiver burden and quality of life (QOL) among caregivers of patients with AD in Japan in a multidimensional manner. Methods: This descriptive, cross-sectional, community-based survey involved administering a web-based questionnaire to live-in caregivers of patients with AD registered with Macromill Inc. BPSD prevalence was measured using the Japanese version of the Neuropsychiatric Inventory-Questionnaire Form. The Japanese version of the Zarit Caregiver Burden Scale (J-ZBI), EQ-5D-5L, and Adult Social Care Outcomes Toolkit for Carers (ASCOT-Carer) were used to assess caregiver burden, health-related QOL, and social care-related QOL, respectively. Results: Of 705 survey responders, 639 (90.6%) and 66 (9.4%) cared for patients with and without BPSD, respectively. Mean caregiver age was 54.6 years, 56.9% were male, and 84.0% cared for parents or in-laws. In the “with BPSD” group, the J-ZBI score was higher (mean difference [95% confidence interval], 6.7 [4.5, 9.0]; p < 0.001), while EQ-5D-5L and ASCOT-Carer scores were lower (–0.076 [–0.134, −0.018; p = 0.010] and −0.101 [–0.168, −0.033]; p = 0.003, respectively) than in the “without BPSD” group. Conclusions: A significant association between increased caregiver burden and BPSD in patients with AD was demonstrated, which may be associated with decreased caregiver healthcare and social care-related QOL.


  • Correlations between agitation and other neuropsychiatric symptoms in each stage of Alzheimer's disease: A re-analysis of CATIE-AD

    by Tomoyuki Nagata, Shinichiro Nakajima, Shinsuke Kito, Shunichiro Shinagawa

    Background: Among neuropsychiatric symptoms (NPSs) of Alzheimer's disease (AD), agitation has been shown to occur commonly in the course of AD, overlapping or comorbid with other NPSs. Objective: The proportion of patients with agitation and the severity of agitation appear to differ depending on the neurocognitive stage of AD, and knowledge about the characteristic comorbid symptom pattern may help in elucidation of the underlying mechanism. Methods: Among 421 clinic-based patients with AD, we re-analyzed the dataset of the Clinical Antipsychotic Trials of Intervention Effectiveness–Alzheimer's Disease (CATIE-AD) to examine the correlations between the scores for agitation and those for other Neuropsychiatric Inventory subscales in each neurocognitive stage of AD (mild, moderate, and severe) classified according to scores in Mini-Mental State Examination. Results: The scores for agitation were positively and robustly correlated with the scores for irritability in all stages of AD, and with the scores for anxiety in the moderate and severe stages. The scores for agitation were also correlated with those for sleep disorders in severe AD stage or disinhibition in the moderate AD stage. Multiple regression analysis identified irritability influencing the agitation in moderate and severe stages, and sleep disorders influencing the agitation in the severe stage. Conclusions: As comorbid NPSs with agitation, characteristic affective, impulsive, and circadian abnormalities may be relevant to generate diverse subsyndromes in AD. Irritability consistently causes agitated behaviors, including refusal to take one's own care, and diurnal rhythm disorder in the severe AD stage may also cause poor acceptance for self-care.


  • Open Access

    The Association Between Distinct Delusional Ideations and Depressive Symptoms in Alzheimer’s Disease: A Re-Analysis of CATIE-AD

    by Tomoyuki Nagata, Shinichiro Nakajima, Shinsuke Kito, Shunichiro Shinagawa

    Background: Delusional ideations, one of neuropsychiatric symptoms (NPSs), are frequently shown in the long-term progression of Alzheimer’s disease (AD), and comorbid with other NPSs including depression or agitation. Despite various types of delusional ideations, the comorbidity between each delusional ideation and depressive symptoms has not been discussed. Objective: The present cross-sectional study is aimed at testing the hypothetical mechanism of comorbid pattern in AD. Methods: Among 421 patients with AD, we analyzed the dataset of the Clinical Antipsychotic Trials of Intervention Effectiveness–Alzheimer’s Disease to compare age, sex, racial type, Mini-Mental State Examination (MMSE) scores, and Neuropsychiatric Inventory (NPI) depression score of between the presence and absence of each delusional ideation (delusion of persecution, theft, jealousy, abandonment, phantom boarder, Capgras syndrome, misidentification of place, or television sign). Next, with the stratification based on MMSE score of < or > = 15 points, we further explored association between delusional ideation and depressive symptom that was found significances in the primary analysis Results: Among eight subtypes of delusional ideations, depression score was higher in those with persecution delusion or Capgras syndrome. Moreover, the Capgras syndrome was associated with presence of depression in severer global cognitive impairment status. Conclusions: As comorbid NPSs of delusional ideation in AD, depressive severity is associated with specific delusional subtype: persecution delusion and Capgras syndrome. Capgras syndrome may be attributable to severe cognitive impairment in addition to depressive symptom. The consideration of pathogenetic differences in the distinct delusional ideations may be helpful for clinicians to select the treatment strategy.


  • Alterations of neuropsychiatric symptoms in dementia patients during hospitalization in a dementia ward

    by Tomoyuki Nagata, Shunichiro Shinagawa, Nobuyuki Kobayashi, Kazuhiro Kondo, Masahiro Shigeta


  • Open Access

    Pathogenesis and Personalized Interventions for Pharmacological Treatment-Resistant Neuropsychiatric Symptoms in Alzheimer’s Disease

    by Tomoyuki Nagata, Shunichiro Shinagawa, Keisuke Inamura, Masahiro Shigeta

    Alzheimer’s disease (AD) is the most common form of dementia, with cognitive impairment as a core symptom. Neuropsychiatric symptoms (NPSs) also occur as non-cognitive symptoms during the disease course, worsening the prognosis. Recent treatment guidelines for NPSs have recommended non-pharmacological treatments as the first line of therapy, followed by pharmacological treatments. However, pharmacological treatment for urgent NPSs can be difficult because of a lack of efficacy or an intolerance, requiring multiple changes in psychotropic prescriptions. One biological factor that might be partly responsible for this difficulty is structural deterioration in elderly people with dementia, which may cause a functional vulnerability affecting the pharmacological response. Other causative factors might include awkward psychosocial interpersonal relations between patients and their caregiver, resulting in distressful vicious circles. Overlapping NPS sub-symptoms can also blur the prioritization of targeted symptoms. Furthermore, consistent neurocognitive reductions cause a primary apathy state and a secondary distorted ideation or perception of present objects, leading to reactions that cannot be treated pharmacologically. The present review defines treatment-resistant NPSs in AD; it may be necessary and helpful for clinicians to discuss the pathogenesis and comprehensive solutions based on three major hypothetical pathophysiological viewpoints: (1) biology, (2) psychosociology, and (3) neurocognition.